Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal human malignancies accounting for over 47,000 cancer related deaths in the U.S. annually. Underlying the dismal prognosis of PDAC is the rapid progression to locally advanced and metastatic disease. Ultimately, this rapid progression results in presentation with late stage disease thereby limiting the number of patients eligible for curative resection, and predisposing those patients eligible for resection to local and metastatic recurrence. Our cytokine screen in premalignant lesion of aggressive (KPC) and indolent (KC) autochthonous PDAC mouse models identified two CXCR3 ligands (PF4 and IP10) as being overexpressed only in the KPC model. Subsequent work identified that CXCR3A and B (the high affinity receptors of IP10 and PF4 respectively) are aberrantly expressed in PDAC cells while IP10 is derived from pancreatic stellate cells (PSCs) and PF4 is derived from platelets and endothelium. in vitro studies show that IP10/CXCR3 mediated signaling results in upregulation of EMT markers including MMPs in PDAC cell line Capan 1 while PF4/CXCR3 signaling resulted in increased ability of Capan 1 cells to survive low attachment conditions and adhere to endothelium. These results suggest that CXCR3 plays a role in the dissemination of PDAC cells at multiple points in the metastatic process. In the presently proposed studies, I will explore the significance and mechanism of CXCR3's contribution to PDAC invasion and metastasis using in vitro and in vivo models to test the hypothesis that ?microenvironment-derived PF4 and IP10 signaling mediated by CXCR3 contributes to the invasion and intravascular phases of the PDAC metastatic process.? To test this hypothesis, I have devised two independent specific aims.
Aim 1, will delineate the mechanism by which PDAC cells induce the expression of IP10 in cancer-associated (CA) PSCs and the modifications in CA-PSC biology that are permissive of IP10 expression. Subsequently, I will explore the overall effects of IP10/CXCR3 signaling on PDAC behavior as well as the mechanism through which IP10 elicits cellular effects in vitro and in vivo using a qRT-PCR based screen coupled with biochemical validation of findings.
Aim 2, focuses on the mechanism by which PF4 affects the intravascular phase of hematogenous PDAC metastasis. Here in vitro work will expand on preliminary data to elucidate signaling cascades activated by PF4/CXCR3 signaling in the context of platelet degranulation and correlate activation of these pathways with outcomes of functional assays. Finally, the effects of and mechanism(s) through which PF4 functions found in vitro will be tested in vivo using a tail vein injection model of PDAC metastasis combined with genetic inhibition of CXCR3B and total CXCR3 expression. Importantly, specific efforts will be made in each aim to distinguish the relative contributions of CXCR3A and B isoforms to the phenomena in question thereby providing clarity to the spatiotemporal importance of each isoform in PDAC progression. Through these aims, I expect to conclusively elucidate the biochemical pathways through which CXCR3A and B function and the role of CXCR3A and B signaling axes in PDAC progression.
Pancreatic cancer (PC) is one of the most lethal human malignancies due in large part to the spread of cancer cells before patients are diagnosed thereby limiting the number of patients that are eligible for surgical treatment, the most effective treatment for PC. Preliminary studies suggest that CXCR3 the receptor of IP10 and PF4 plays a role in promoting the spread PC cells. This study hopes to define the mechanism by which IP10/CXCR3 and PF4/CXCR3 cell signaling contribute to this aggressive behavior with hopes that these pathways can be targeted to limit and reverse the spread of PC cells thereby improving the prognosis of patients with PC.
| Cannon, Andrew; Thompson, Christopher; Hall, Bradley R et al. (2018) Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes Cancer 9:78-86 |
